Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Silo Pharma Inc SILO

Healthcare Biotechnology
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and... see more

Recent & Breaking News (NDAQ:SILO)

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

GlobeNewswire 6 days ago

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

GlobeNewswire June 7, 2024

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire June 6, 2024

Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire June 5, 2024

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

GlobeNewswire June 4, 2024

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

GlobeNewswire May 21, 2024

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

GlobeNewswire May 14, 2024

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

GlobeNewswire April 23, 2024

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic

GlobeNewswire April 10, 2024

Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic

GlobeNewswire March 20, 2024

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

GlobeNewswire March 18, 2024

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

GlobeNewswire February 28, 2024

Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

GlobeNewswire February 14, 2024

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

GlobeNewswire February 1, 2024

Silo Pharma Announces Positive Results in Alzheimer's Disease Study

GlobeNewswire January 24, 2024

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

GlobeNewswire January 4, 2024

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

GlobeNewswire December 28, 2023

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

GlobeNewswire November 21, 2023

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

GlobeNewswire November 8, 2023

Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

GlobeNewswire October 16, 2023